TYMS and non-small cell lung carcinoma: Overall, the magnitude of 18F-FLT flares detected among the subset of patients has the potential to be used in the future to develop new TS inhibitors, evaluate the effect of modulators [9,10], and to evaluate further strategies on the personalisation of pemetrexed–immunotherapy use in advanced non-squamous NSCLC.